» Articles » PMID: 22721718

Analysis of Ubiquitin E3 Ligase Activity Using Selective Polyubiquitin Binding Proteins

Overview
Specialties Biochemistry
Biophysics
Date 2012 Jun 23
PMID 22721718
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

The ubiquitin proteasome pathway controls the cellular degradation of ~80-90% of the proteome in a highly regulated manner. In this pathway, E3 ligases are responsible for the conjugation of ubiquitin to protein substrates which can lead to their destruction by the 26S proteasome. Aberrant E3 ligases have been implicated in several diseases and are widely recognized as attractive targets for drug discovery. As researchers continue to characterize E3 ligases, additional associations with various disease states are being exposed. The availability of assays that allow rapid analysis of E3 ligase activity is paramount to both biochemical studies and drug discovery efforts aimed at E3 ligases. To address this need, we have developed a homogenous assay for monitoring ubiquitin chain formation using Tandem Ubiquitin Binding Entities (TUBEs). TUBEs bind selectively to polyubiquitin chains versus mono-ubiquitin thus enabling the detection of polyubiquitin chains in the presence of mono-ubiquitin. This assay reports on the proximity between the protein substrate and TUBEs as a result of polyubiquitin chain formation by an E3 ligase. This homogenous assay is a step forward in streamlining an approach for characterizing and quantitating E3 ligase activity in a rapid and cost effective manner. This article is part of a Special Issue entitled: Ubiquitin Drug Discovery and Diagnostics.

Citing Articles

Targeting TRIM Proteins: A Quest towards Drugging an Emerging Protein Class.

DAmico F, Mukhopadhyay R, Ovaa H, Mulder M Chembiochem. 2021; 22(12):2011-2031.

PMID: 33482040 PMC: 8251876. DOI: 10.1002/cbic.202000787.


Resolving the Complexity of Ubiquitin Networks.

Kliza K, Husnjak K Front Mol Biosci. 2020; 7:21.

PMID: 32175328 PMC: 7056813. DOI: 10.3389/fmolb.2020.00021.


The MALDI-TOF E2/E3 Ligase Assay as Universal Tool for Drug Discovery in the Ubiquitin Pathway.

De Cesare V, Johnson C, Barlow V, Hastie J, Knebel A, Trost M Cell Chem Biol. 2018; 25(9):1117-1127.e4.

PMID: 30017913 PMC: 6162346. DOI: 10.1016/j.chembiol.2018.06.004.


Real-time detection of N-end rule-mediated ubiquitination via fluorescently labeled substrate probes.

Mot A, Prell E, Klecker M, Naumann C, Faden F, Westermann B New Phytol. 2017; 217(2):613-624.

PMID: 28277608 PMC: 5763331. DOI: 10.1111/nph.14497.


Ndfip-mediated degradation of Jak1 tunes cytokine signalling to limit expansion of CD4+ effector T cells.

OLeary C, Riling C, Spruce L, Ding H, Kumar S, Deng G Nat Commun. 2016; 7:11226.

PMID: 27088444 PMC: 4837450. DOI: 10.1038/ncomms11226.


References
1.
Kane S, Fleener C, Zhang Y, Davis L, Musselman A, Huang P . Development of a binding assay for p53/HDM2 by using homogeneous time-resolved fluorescence. Anal Biochem. 2000; 278(1):29-38. DOI: 10.1006/abio.1999.4413. View

2.
Inoue S, Orimo A, Hosoi T, Kondo S, Toyoshima H, Kondo T . Genomic binding-site cloning reveals an estrogen-responsive gene that encodes a RING finger protein. Proc Natl Acad Sci U S A. 1993; 90(23):11117-21. PMC: 47933. DOI: 10.1073/pnas.90.23.11117. View

3.
Pickart C . Mechanisms underlying ubiquitination. Annu Rev Biochem. 2001; 70:503-33. DOI: 10.1146/annurev.biochem.70.1.503. View

4.
Hjerpe R, Aillet F, Lopitz-Otsoa F, Lang V, England P, Rodriguez M . Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding entities. EMBO Rep. 2009; 10(11):1250-8. PMC: 2775171. DOI: 10.1038/embor.2009.192. View

5.
Bodine S, Latres E, Baumhueter S, Lai V, Nunez L, Clarke B . Identification of ubiquitin ligases required for skeletal muscle atrophy. Science. 2001; 294(5547):1704-8. DOI: 10.1126/science.1065874. View